The Insider, Steven Gilman Unloaded 1,334 Shares of Keryx Biopharmaceuticals, Inc. (KERX); Bryn Mawr Bank (BMTC) Sellers Decreased By 34.66% Their Shorts

Bryn Mawr Bank Corporation (NASDAQ:BMTC) Logo

Bryn Mawr Bank Corporation (NASDAQ:BMTC) had a decrease of 34.66% in short interest. BMTC’s SI was 109,700 shares in June as released by FINRA. Its down 34.66% from 167,900 shares previously. With 60,300 avg volume, 2 days are for Bryn Mawr Bank Corporation (NASDAQ:BMTC)’s short sellers to cover BMTC’s short positions. The SI to Bryn Mawr Bank Corporation’s float is 0.65%. It closed at $47.1 lastly. It is down 14.27% since June 13, 2017 and is uptrending. It has outperformed by 1.70% the S&P500. Some Historical BMTC News: ; 20/04/2018 – BRYN MAWR BANK CORP BMTC.O : KBW RAISES TARGET PRICE TO $56 FROM $54; 02/04/2018 – Bryn Mawr Trust Rebrands Powers Craft Insurance Division as BMT Insurance Advisors; 19/04/2018 – Bryn Mawr Bank 1Q EPS 75c; 05/03/2018 Bryn Mawr Bank Closes Above 50-Day Moving Average: Technicals; 01/05/2018 – Bryn Mawr Trust Grows Its BMT Insurance Advisors Announcing The Acquisition Of Domenick & Associates; 19/04/2018 – Bryn Mawr Bank 1Q Net Interest Income $37.4 Million; 19/04/2018 – Bryn Mawr Bank 1Q Net $15.3M; 19/04/2018 – DJ Bryn Mawr Bank Corporation, Inst Holders, 1Q 2018 (BMTC); 02/04/2018 – Local Blogger, Bryn Nowell, Three Time Finalist for International Pet Industry Award; 17/04/2018 – Tripp Lite Appoints Bryn Morgan as Vice President of International Business

Bryn Mawr Bank Corporation operates as the bank holding firm for The Bryn Mawr Trust Company that provides commercial and retail banking services to individuals and businesses. The company has market cap of $953.25 million. It accepts deposit products, such as non-interest-bearing demand deposits, savings, NOW accounts, and market rate accounts. It has a 35.68 P/E ratio. The companyÂ’s loan and lease portfolio comprises commercial and residential mortgage construction, commercial and industrial, and consumer loans, as well as home equity lines and loans; and leasing services.

Since February 5, 2018, it had 2 insider purchases, and 2 insider sales for $144,799 activity. Clement Michael Joseph had bought 2,800 shares worth $122,763 on Thursday, February 8. On Friday, February 16 the insider HOLLAND WENDELL F sold $157,620. $155,935 worth of Bryn Mawr Bank Corporation (NASDAQ:BMTC) was sold by Jenkins Scott Mahaley. On Monday, February 5 the insider Calderin Diego F. bought $45,993.

Investors sentiment increased to 1.35 in 2018 Q1. Its up 0.08, from 1.27 in 2017Q4. It improved, as 8 investors sold Bryn Mawr Bank Corporation shares while 38 reduced holdings. 17 funds opened positions while 45 raised stakes. 14.46 million shares or 1.04% more from 14.31 million shares in 2017Q4 were reported. 6,201 are held by Qs Investors Lc. Dean Associates Limited Liability Com reported 78,796 shares. Group Inc Inc owns 12,156 shares for 0% of their portfolio. Brandywine Global Invest Management Limited Liability Company holds 0% or 4,503 shares in its portfolio. Federated Invsts Inc Pa holds 60 shares. Credit Suisse Ag has invested 0% in Bryn Mawr Bank Corporation (NASDAQ:BMTC). First Mercantile, Tennessee-based fund reported 1,270 shares. Bnp Paribas Arbitrage Sa owns 0% invested in Bryn Mawr Bank Corporation (NASDAQ:BMTC) for 4,017 shares. California Employees Retirement Systems holds 0% or 39,483 shares. Deutsche Bancorporation Ag reported 0% in Bryn Mawr Bank Corporation (NASDAQ:BMTC). Wells Fargo And Company Mn owns 73,213 shares or 0% of their US portfolio. Goldman Sachs Incorporated holds 0.01% or 518,574 shares. Architects holds 0.05% or 5,589 shares. 21,648 were accumulated by Citadel Advisors Ltd Liability Corp. Geode Mngmt Ltd Company invested in 174,174 shares.

More recent Bryn Mawr Bank Corporation (NASDAQ:BMTC) news were published by: which released: “Bryn Mawr Trust Appoints Christopher P. McGill Market President, Philadelphia and Southern New Jersey” on June 12, 2018. Also published the news titled: “Financial upgrades / downgrades” on June 11, 2018.‘s news article titled: “Research Report Identifies Bryn Mawr Bank, Whitestone REIT, Surgery Partners, PennantPark Floating Rate Capital …” with publication date: May 24, 2018 was also an interesting one.

Among 5 analysts covering Bryn Mawr Bank (NASDAQ:BMTC), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bryn Mawr Bank had 12 analyst reports since July 28, 2015 according to SRatingsIntel. On Monday, August 31 the stock rating was upgraded by Zacks to “Sell”. On Monday, July 24 the stock rating was upgraded by Boenning \u0026 Scattergood to “Outperform”. Keefe Bruyette & Woods maintained the stock with “Buy” rating in Thursday, April 19 report. The company was maintained on Thursday, December 21 by Keefe Bruyette & Woods. As per Tuesday, January 10, the company rating was downgraded by FIG Partners. The rating was downgraded by Sandler O’Neill on Friday, June 8 to “Hold”. As per Friday, July 21, the company rating was maintained by Keefe Bruyette & Woods. The company was maintained on Monday, February 26 by Keefe Bruyette & Woods. Keefe Bruyette & Woods maintained the shares of BMTC in report on Tuesday, October 3 with “Buy” rating. Keefe Bruyette & Woods maintained Bryn Mawr Bank Corporation (NASDAQ:BMTC) rating on Monday, June 26. Keefe Bruyette & Woods has “Buy” rating and $4500 target.

The stock decreased 0.69% or $0.035 during the last trading session, reaching $5.025. About 48,617 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 18.22% since June 13, 2017 and is downtrending. It has underperformed by 30.79% the S&P500. Some Historical KERX News: ; 25/05/2018 – KERYX BIOPHARMACEUTICALS ANNOUNCES DATA FROM AN INVESTIGATOR SPONSORED TRIAL OF FERRIC CITRATE IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE IN A LATE-BREAKING PRESENTATION AT THE 55TH ANNUAL; 30/04/2018 – Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue; 06/03/2018 Keryx Biopharmaceuticals to Webcast its Presentation at the Cowen 38th Annual Healthcare Conference on March 12, 2018; 19/04/2018 – Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA; 04/04/2018 – KERYX BIOPHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM THE PHASE 3 TRIAL OF AURYXIA® (FERRIC CITRATE) FOR IRON DEFICIENCY ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS, IN THE…; 29/05/2018 – Keryx Pharmaceuticals Announces Upcoming Investor Presentations; 25/05/2018 – Keryx Biopharmaceuticals Announces Data from an lnvestigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen; 10/05/2018 – Keryx Biopharm 1Q Loss/Shr 18c; 21/04/2018 – DJ Keryx Biopharmaceuticals Inc, Inst Holders, 1Q 2018 (KERX); 24/05/2018 – Keryx Presenting at ERA-EDTA Annual Congress 2018 Tomorrow

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on July, 26. They expect $-0.16 EPS, up 23.81% or $0.05 from last year’s $-0.21 per share. After $-0.18 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Since January 5, 2018, it had 0 insider purchases, and 19 insider sales for $303,859 activity. $13,612 worth of stock was sold by Holmes Scott A on Monday, January 29. Neylan John F. had sold 1,158 shares worth $6,589 on Tuesday, May 15. On Thursday, February 15 Adams Brian sold $27,186 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 5,652 shares. $44,064 worth of stock was sold by Carberry Christine A. on Thursday, January 18. 1,667 shares were sold by Cameron Kevin J, worth $8,702. 1,067 shares were sold by Madison Greg, worth $5,004 on Friday, January 5. The insider GILMAN STEVEN C sold $6,958.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $605.64 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.72’s average target is 73.53% above currents $5.025 stock price. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 8 by Stifel Nicolaus. The rating was maintained by Morgan Stanley on Tuesday, July 25 with “Equal-Weight”. On Tuesday, August 11 the stock rating was initiated by FBR Capital with “Mkt Perform”. On Thursday, August 6 the stock rating was maintained by BTIG Research with “Sell”. The stock has “Hold” rating by Cowen & Co on Thursday, July 27. The firm has “Buy” rating by Maxim Group given on Thursday, August 6. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Hold” rating given on Tuesday, August 2 by Stifel Nicolaus. The rating was downgraded by JP Morgan to “Neutral” on Friday, February 26. The company was maintained on Friday, July 8 by Maxim Group. The stock has “Sell” rating by Zacks on Friday, August 28.

As disclosed in a legal form which was filled with the DC-based SEC on June 12, 2018, Steven Gilman an insider in Keryx Biopharmaceuticals Inc and currently director, made a sale of shares worth $6,830 US Dollars in the corporation. He sold 1,334 shares, at average $5.1 per share. In the last 30 days, he also sold 1,333 shares that are worth $6,958 USD. Currently, he owns a total of 17,333 shares or 0.01% of Keryx Biopharmaceuticals Inc’s market capitalization (total value of the shares outstanding).

Bryn Mawr Bank Corporation (NASDAQ:BMTC) Institutional Positions Chart